Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 4.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 322,458 shares of the medical equipment provider's stock after acquiring an additional 12,850 shares during the period. Nomura Asset Management Co. Ltd. owned approximately 0.09% of Intuitive Surgical worth $158,414,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hazlett Burt & Watson Inc. raised its holdings in shares of Intuitive Surgical by 5.8% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider's stock worth $177,000 after acquiring an additional 20 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. raised its stake in Intuitive Surgical by 4.1% during the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider's stock valued at $247,000 after purchasing an additional 20 shares in the last quarter. Ullmann Wealth Partners Group LLC raised its stake in Intuitive Surgical by 1.6% during the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider's stock valued at $653,000 after purchasing an additional 21 shares in the last quarter. Meeder Advisory Services Inc. lifted its position in Intuitive Surgical by 0.3% during the third quarter. Meeder Advisory Services Inc. now owns 7,386 shares of the medical equipment provider's stock valued at $3,629,000 after purchasing an additional 22 shares during the last quarter. Finally, One Wealth Management Investment & Advisory Services LLC grew its stake in shares of Intuitive Surgical by 3.4% in the 2nd quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider's stock worth $310,000 after buying an additional 23 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 238 shares of the firm's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $477.50, for a total value of $113,645.00. Following the completion of the transaction, the executive vice president now owns 5,506 shares of the company's stock, valued at approximately $2,629,115. This trade represents a 4.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Jamie Samath sold 108 shares of Intuitive Surgical stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $542.06, for a total transaction of $58,542.48. Following the sale, the chief financial officer now owns 8,757 shares of the company's stock, valued at $4,746,819.42. The trade was a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,723 shares of company stock worth $26,241,747. 0.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Morgan Stanley raised shares of Intuitive Surgical from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $522.00 to $650.00 in a report on Monday, December 2nd. Erste Group Bank raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Tuesday, November 19th. JPMorgan Chase & Co. boosted their target price on Intuitive Surgical from $495.00 to $575.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Stifel Nicolaus raised their price target on Intuitive Surgical from $525.00 to $610.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $538.00 price objective (up from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $541.33.

Intuitive Surgical Stock Down 2.1 %

Shares of NASDAQ ISRG traded down $11.55 during trading hours on Monday, hitting $538.86. 1,428,757 shares of the stock were exchanged, compared to its average volume of 1,445,554. Intuitive Surgical, Inc. has a 12 month low of $309.80 and a 12 month high of $556.23. The firm has a fifty day moving average price of $517.16 and a 200-day moving average price of $475.65. The company has a market cap of $191.93 billion, a PE ratio of 86.63, a PEG ratio of 5.41 and a beta of 1.38.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.